Breast Cancer
STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)
- Details
ClinicalTrials.gov ID:
NCT03975647
Diagnosis Type:
NA
USOR Number:
- Address
1580 Beam Avenue
Maplewood, MN 55109
P: (651) 779-7978